Hsbc Holdings PLC Purchases Shares of 71,816 Revolution Medicines, Inc. $RVMD

Hsbc Holdings PLC acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 71,816 shares of the company’s stock, valued at approximately $13,458,000.

A number of other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after purchasing an additional 1,056,792 shares during the period. State of Wyoming acquired a new position in Revolution Medicines in the 2nd quarter valued at $1,769,000. Handelsbanken Fonder AB increased its position in Revolution Medicines by 243.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company’s stock worth $39,755,000 after buying an additional 150,500 shares during the period. Eagle Health Investments LP bought a new position in Revolution Medicines during the 4th quarter worth $9,231,000. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Revolution Medicines during the second quarter worth $37,547,000. Institutional investors own 94.34% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on RVMD shares. Wolfe Research restated an “outperform” rating and issued a $220.00 price target on shares of Revolution Medicines in a research note on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research note on Friday, July 17th. Wedbush boosted their price objective on shares of Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday. Sanford C. Bernstein increased their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a research report on Friday, August 21st. Finally, Truist Financial raised their target price on shares of Revolution Medicines from $231.00 to $239.00 and gave the stock a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $193.28.

Revolution Medicines Trading Up 2.7%

Shares of Revolution Medicines stock opened at $221.15 on Friday. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines, Inc. has a 12-month low of $37.56 and a 12-month high of $224.31. The company has a market capitalization of $47.40 billion, a price-to-earnings ratio of -25.07 and a beta of 1.39. The firm’s 50-day moving average price is $192.43 and its two-hundred day moving average price is $148.17.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the prior year, the business posted ($1.31) EPS. On average, analysts forecast that Revolution Medicines, Inc. will post -8.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other news, Director Sushil Patel sold 5,580 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the completion of the transaction, the director owned 21,656 shares of the company’s stock, valued at approximately $4,071,111.44. The trade was a 20.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Stephen Michael Kelsey sold 4,175 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total value of $651,801.00. Following the sale, the insider owned 291,876 shares of the company’s stock, valued at approximately $45,567,681.12. This represents a 1.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is currently owned by insiders.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.